Emisphere and Roche To Develop Oral Formulations of Large Molecules

July 27, 2006
BioPharm International Editors

Emisphere Technologies, Inc. (Tarrytown, NY, www.emisphere.com) has signed a multi-product research agreement with Roche (Basel, Switzerland, www.roche.com) to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of Roche molecules.

Emisphere Technologies, Inc. (Tarrytown, NY, www.emisphere.com) has signed a multi-product research agreement with Roche (Basel, Switzerland, www.roche.com) to explore the use of Emisphere’s eligen technology in feasibility studies for new oral formulations of Roche molecules. Research, funded by Roche, will be conducted at both companies’ sites. Emisphere’s eligen technology is an oral drug delivery platform based on the use of synthetic chemical compounds known as EMISPHERE delivery agents or carriers. These molecules facilitate transportation of therapeutic macromolecules across biological membranes to exert their desired pharmacological effect.

Related Content:

News